<unk>  is an tyrosine kinase inhibitor that is FDA approved for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC).   Common adverse reactions include hypertension, fatigue, diarrhea, arthralgia/myalgia, decreased appetite, weight decreased, nausea, stomatitis, headache, vomiting, proteinuria, palmar-plantar erythrodysesthesia (PPE) syndrome, abdominal pain, and dysphonia. pneumonia, hypertension , and dehydration ..
Lenvatinib
Neratinib
Fostamatinib
Brigatinib
Dasatinib
Lorlatinib
Afatinib
Acalabrutinib